Market outlook of the global cervical cancer market

Cervical cancer is generally characterized by the abnormal growth of the cancerous cells in the tissues of the cervix and may manifest itself as a squamous-cell carcinoma or adenocarcinoma. According to the cervical cancer industry analysis, Technavio’s analyst has estimated factors like the rising public awareness about vaccines and the dominance of initial screening tests to result in this market’s modest growth rate of almost 5% by 2019.

Geographically, the Americas are expected to account for almost 49% of the total market share by 2019. In the Americas, the US region is envisaged to be the highest revenue contributor due to the advent of Avastin targeted therapy and the vaccine Gardasil 9.

Application-based segmentation of the cervical cancer market

• Prophylactic vaccines market
• Therapeutic drugs market

Based on the cervical cancer market outlook, Technavio’s market research analysts have estimated the prophylactic vaccines market segment to show the highest market growth rate during the forecast period. A high market growth rate of this segment can be attributed to factors like the launch of effective vaccines, like Merck's Gardasil and GSK's Cervarix, during the forecast period. This factor will increase the cervical cancer market growth.

Segmentation by type of therapy and analysis of the cervical cancer market

• Chemotherapy
• Targeted therapy
• Vaccines

The vaccines segment is expected to account for the largest market share during the forecast period. This segment contains popular vaccines like Gardasil, Gardasil 9, and Cervarix that aid in the prevention of different types of cervical cancer. Consequently, analysts estimate this segment to dominate the market during the next five years.

Competitive landscape and key vendors

This market is characterized by the presence of some prominent vendors who dominate this market during the forecast period due to their superior product portfolio. The launch of effective drugs and vaccines like Gardasil 9 is expected to intensify the competition between the vendors.

Key leading vendors in this market are 

• F. Hoffmann-La Roche
• GlaxoSmithKline
• Merck

Other prominent vendors in this market are Advaxis, Bionor Pharma, Dendreon, Inovio Pharmaceuticals, ISA Pharmaceuticals, Otsuka Pharmaceutical, Profectus, Virometix, and Zeria Pharmaceutical.

Key questions answered in the report include

• What will the market size and the growth rate be in 2019?
• What are the key factors driving the global cervical cancer market?
• What are the key market trends impacting the growth of the global cervical cancer market?
• What are the challenges to market growth?
• Who are the key vendors in the global cervical cancer market?
• What are the market opportunities and threats faced by the vendors in the global cervical cancer market?
• Trending factors influencing the market shares of APAC, EMEA, and the Americas?
• What are the key outcomes of the five forces analysis of the global cervical cancer market?

Technavio also offers customization on reports based on specific client requirement.

Related reports

• Global Cervical Cancer Diagnostic Tests Market 2014-2018
• Global Prostate Cancer Devices Market 2015-2019
• Global Kidney Cancer Drugs Market 2015-2019
• Global Cancer Vaccines Market 2015-2019